We are live on !
Find out more
BB Biotech Portfolio holdings
AUM
$3.98B
Turnover
8.33%
1-Year Est. Return
15.47%
This Fund
S&P 500
This Quarter Est. Return
+31.41%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$3.98B
AUM Growth
+$856M
(+27%)
Cap. Flow
+$11.5M
Cap. Flow % of AUM
Cap. Flow %
0.29%
Top 10 Holdings %
Top 10 Hldgs %
64.68%
Holding
36
New
2
Increased
14
Reduced
6
Closed
1
Avg Time Held
2.9
years
Top 10 Avg Time Held
3
years
Top 20 Avg Time Held
3.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CRISPR Therapeutics
CRSP
|
+$28M |
| 2 |
Nektar Therapeutics
NKTR
|
+$25.3M |
| 3 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
+$17.9M |
| 4 |
Audentes Therapeutics, Inc
BOLD
|
+$17.2M |
| 5 |
SANGAMO THERAPEUTICS INC
SGMO
|
+$13.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ionis Pharmaceuticals
IONS
|
+$65.6M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$25.5M |
| 3 |
Incyte
INCY
|
+$15.3M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$13M |
| 5 |
Gilead Sciences
GILD
|
+$12.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
ALDR
26
DELISTED
Alder Biopharmaceuticals
ALDR
| $37.8M | 0.95% |
2,766,008
| – | – |
2015 Q2
15 quarters
|
|
|
27
CRISPR Therapeutics
CRSP
$4.84B
| $29M | 0.73% |
+810,462
| New | +$28M |
2019 Q1
0 quarters
|
|
28
Scholar Rock
SRRK
$4.9B
| $27.8M | 0.7% |
1,476,839
+196,861
| +15% | +$3.47M |
2018 Q3
2 quarters
|
|
29
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $26.8M | 0.67% |
2,200,000
| – | – |
2016 Q2
11 quarters
|
|
|
30
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $25.3M | 0.64% |
2,650,000
+1,300,000
| +96% | +$13.3M |
2018 Q4
1 quarter
|
|
31
DELISTED
Kezar Life Sciences
KZR
| $21.7M | 0.54% |
122,050
+40,207
| +49% | +$7.92M |
2018 Q4
1 quarter
|
|
32
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $11.2M | 0.28% |
671,925
| – | – |
2018 Q2
3 quarters
|
|
33
DELISTED
Cidara Therapeutics
CDTX
| $6.08M | 0.15% |
114,764
| – | – |
2015 Q4
13 quarters
|
|
34
Novavax
NVAX
$1.78B
| $4.59M | 0.12% |
416,500
| – | – |
2014 Q3
18 quarters
|
|
35
Q32 Bio
QTTB
$232M
| $2.53M | 0.06% |
+5,074
| New | +$2.27M |
2019 Q1
0 quarters
|
|
|
36
Regeneron Pharmaceuticals
REGN
$80.5B
| – | – |
-68,156
| Closed | -$25.5M | – |
|
Similar funds
SA
BB Biotech's Q1 2019 Portfolio in Review
As of Q1 2019, BB Biotech held 36 positions worth $3.98B, up 27% from $3.12B the previous quarter. Its ten largest holdings account for 65% of the portfolio.
BB Biotech's Q1 2019 filing shows 2 new, 14 increased, 6 reduced and 1 closed positions. Its largest new stake was CRISPR Therapeutics: 810,462 shares worth $29M. The largest sale was Ionis Pharmaceuticals, an estimated $65.6M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- BB Biotech's largest Q1 2019 buy was CRISPR Therapeutics: 810,462 shares worth $29M.
- BB Biotech added most to Nektar Therapeutics in Q1 2019, an estimated $25.3M increase.
- BB Biotech's biggest Q1 2019 reduction was Ionis Pharmaceuticals, cutting an estimated $65.6M.
- BB Biotech fully exited Regeneron Pharmaceuticals in Q1 2019, selling an estimated $25.5M.
- BB Biotech's ten largest holdings make up 65% of its $3.98B portfolio in Q1 2019.
- BB Biotech opened 2 new positions and closed 1 in Q1 2019.
- BB Biotech's portfolio value rose 27% quarter-over-quarter to $3.98B.
Based on BB Biotech's 13F filing for Q1 2019, filed 13 May 2019.